R. Scott Greer's Insider Trades & SAST Disclosures
R. Scott Greer's most recent trade in Nektar Therapeutics was a trade of 120,000 Stock Option done . Disclosure was reported to the exchange on Dec. 31, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern R. Scott Greer.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Nektar Therapeutics | R. Scott Greer | Director | 31 Dec 2024 | 120,000 | 120,000 | - | - | Stock Option | ||
| Nektar Therapeutics | R. Scott Greer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 20,400 | 20,400 | - | - | Stock Option | |
| Nektar Therapeutics | R. Scott Greer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 10,200 | 303,574 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | R. Scott Greer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2021 | 12,500 | 0 | - | - | Stock Option | |
| Nektar Therapeutics | R. Scott Greer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.80 per share. | 09 Nov 2021 | 12,500 | 293,374 (0%) | 0% | 12.8 | 160,000 | Common Stock |
| Nektar Therapeutics | R. Scott Greer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2021 | 20,400 | 20,400 | - | - | Stock Option | |
| Nektar Therapeutics | R. Scott Greer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2021 | 10,200 | 280,874 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | R. Scott Greer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.70 per share. | 31 Aug 2021 | 45,000 | 270,674 (0%) | 0% | 12.7 | 571,500 | Common Stock |
| Nektar Therapeutics | R. Scott Greer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2021 | 45,000 | 0 | - | - | Stock Option | |
| Inogen Inc | R. Scott Greer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2021 | 2,754 | 30,775 (0%) | 0% | 0 | Common Stock | |
| Inogen Inc | R. Scott Greer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2021 | 10,000 | 0 | - | - | Stock Option (right to buy) | |
| Inogen Inc | R. Scott Greer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 44.19 per share. | 03 Feb 2021 | 10,000 | 28,021 (0%) | 0% | 44.2 | 441,900 | Common Stock |
| Inogen Inc | R. Scott Greer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2021 | 6,666 | 0 | - | - | Stock Option (right to buy) | |
| Inogen Inc | R. Scott Greer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 46.66 per share. | 03 Feb 2021 | 6,666 | 14,687 (0%) | 0% | 46.7 | 311,036 | Common Stock |
| Inogen Inc | R. Scott Greer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2021 | 3,334 | 0 | - | - | Stock Option (right to buy) | |
| Inogen Inc | R. Scott Greer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.21 per share. | 03 Feb 2021 | 3,334 | 18,021 (0%) | 0% | 43.2 | 144,062 | Common Stock |
| Nektar Therapeutics | R. Scott Greer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.80 per share. | 05 Jan 2021 | 40,000 | 225,674 (0%) | 0% | 13.8 | 552,000 | Common Stock |
| Nektar Therapeutics | R. Scott Greer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2021 | 40,000 | 0 | - | - | Stock Option | |
| Nektar Therapeutics | R. Scott Greer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2020 | 18,200 | 18,200 | - | - | Stock Option | |
| Nektar Therapeutics | R. Scott Greer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2020 | 9,100 | 185,674 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | R. Scott Greer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.24 per share. | 09 Jul 2020 | 40,000 | 191,583 (0%) | 0% | 9.2 | 369,600 | Common Stock |
| Nektar Therapeutics | R. Scott Greer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jul 2020 | 40,000 | 0 | - | - | Stock Option | |
| Nektar Therapeutics | R. Scott Greer | Director | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 09 Jul 2020 | 15,009 | 176,574 (0%) | 0% | 25 | 375,225 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges